<i id='C09E2A4875'><strike id='C09E2A4875'><tt id='C09E2A4875'><pre id='C09E2A4875'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
Woodcock on FDA’s accelerated approval and her next chapter 
What does generative AI mean for health care? We asked experts 
Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates 
Drug repurposing or repositioning? The language matters 
Health AI adoption puts security, privacy startups on investors' radar 
Walensky prepares to leave CDC — and Congress — behind 
UnitedHealth increases loan offers after Change Healthcare outage 
Sports medicine is finally prioritizing gender equality 
Positive childhood experiences can help future health 
Novavax promises a turnaround & Lilly roils the obesity market 
Argenx readies a blockbuster opportunity with drug for autoimmune disease 
Malaria cases in Florida and Texas: Here’s what you need to know 
New Ultima Genomics DNA sequencer can read genome for $100
Moonlake's readout produced a cash windfall. Risks remain 
